Failure of Miltefosine Treatment in Two Dogs with Natural Leishmania infantum Infection

Table 3

Case number 2: clinical score, therapy, and hematological and biochemical analysis of the second dog affected by canine leishmaniasis.

Follow-up	Clinical score	Therapy	RBC; ×10^3/L	Hb; g/dL	PCV%	PLT; /uL	TP; g/dL	ALB%	G%	A/G	IFAT
D0	11/86	MLT + A; 28/d	5100	11.9	32	288.000	7.8	35.5	30.1	0.5	1 : 640
D30	7/86	A	5360	12.7	32.5	272.000	8.3	36.1	25.5	0.6	1 : 640
D90	3/86	A	6550	15.4	40.4	186.000	6.4	41.2	17.6	0.7	1 : 320
D150	7/86	MLT + A; 28/d	5970	13.9	37.3	172.000	7.2	33.7	24.7	0.5	1 : 320
D180	11/86	MA; 28/d	4280	8.9	26.3	295.000	8	37.6	26.4	0.6	1 : 320
D210	5/86	A	6470	15.3	41.2	197.000	5.9	32	19.8	0.5	1 : 320
D270	2/86	A	6700	14.6	40.2	307.000	7.4	38.6	14.7	0.63	1 : 160
D450	0/86	A	6760	14.5	42.7	230.000	6.9	46.3	13.9	0.7	1 : 160

RBC: red cells × 10/L (reference range 5700–8800 × 10/L).
Hemoglobin: Hb (reference range: 12.9–18.4 g/dL).
Haematocrit: PCV (reference range: 37.1–57%).
Platelet: PLT (reference range: 143300–400000/uL).
Total protein: TP (reference range: 6–8 g/dL).
Albumine: ALB (reference range: 46.3–58.5%).
Gamma globuline: G (reference range: 5.3–9.9%).
Albumine/globuline: A/G (reference rang: 0.8–1.7).
IFAT: immunofluorescence antibody test (reference range: <1 : 80).
Miltefosine: MLT.
Allopurinol: A.
Meglumine antimoniate: MA.
Days: d.